Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Ichnos Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class Il-1 RAP Antagonist Monoclonal Antibody

Details:

Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.

Lead Product(s): ISB 880

Therapeutic Area: Immunology Product Name: ISB 880

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Almirall

Deal Size: Undisclosed Upfront Cash: $23.6 million

Deal Type: Licensing Agreement December 14, 2021

ASK
US

Upload
your Pipeline Activity

Polyneuron Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy

Details:

Regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN?1007 for the treatment of anti-MAG neuropathy.

Lead Product(s): PN-1007

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY